Nigericin sodium salt

SKU: orb1304550

Description

Nigericin sodium salt

Research Area

Immunology & Inflammation, Infectious Disease & Virology, Pharmacology & Drug Discovery, Signal Transduction

Key Properties

• CAS Number: 28643-80-3
• MW: 746.94
• Purity: 98.31%
• Formula: C₄₀H₆₇NaO₁₁
• SMILES: [Na+].[H][C@@]1(C[C@H](C)[C@@]([H])(O1)[C@]1(C)CC[C@@]([H])(O1)[C@]1(C)C[C@@H](C)[C@]2(O1)O[C@]([H])(C[C@@]1([H])CC[C@H](C)[C@@]([H])(O1)[C@@H](C)C([O-])=O)C[C@@H](OC)[C@H]2C)[C@@]1([H])O[C@@](O)(CO)[C@H](C)C[C@@H]1C
• Target: NOD,Potassium Channel,Antibacterial,Antibiotic,NOD-like Receptor (NLR)
• Solubility: DMSO:< 1 mg/mL (insoluble or slightly soluble);Methanol:22.72 mg/mL (30.42 mM);Ethanol:120 mg/mL (160.66 mM);H2O:< 1 mg/mL (insoluble or slightly soluble)

Bioactivity

• Target IC50:
  4T1 cells:2.505 μM|SW116 cells:15.86 ± 0.18 μMol|S18 cells:2.03 ± 0.55 μM|S26 cells:4.77 ± 2.35 μM|HT29 cells:12.92 ± 0.25 μMol|MDA-MB-231 cells:2.881 μM
• In Vivo:
  METHODS: To detect anti-tumor activity in vivo Nigericin sodium (2 mg/kg, subcutaneous injection every two days) and anti-PD-1 (250 μg/mouse, intraperitoneal injection once a week) were administered to BAL-/- mice bearing triple-negative mammary adenocarcinoma tumor 4T1 for two weeks. Results: PD-1 antibody alone did not show significant antitumor effects, while Nigericin sodium showed moderate antitumor effects.The combination of Nigericin sodium and anti-PD-1 almost completely inhibited tumor growth. METHODS: To investigat the effects of aging on inflammatory vesicle function, Nigericin sodium (0.005 mg/g, 250 μL) was administered as a Single intraperitoneal injection once daily for seven days to influenza virus-infected BAL-/- mice. Results: Treatment with Nigericin sodium during influenza infection increased IL-1β production, increased capase-1 activity, and reduced morbidity and mortality in aged mice. During influenza virus infection, NLRP3 inflammatory vesicle activity is impaired in aged mice, and Nigericin sodium treatment rescues NLRP3 in aged hosts
• In Vitro:
  METHODS: Triple-negative breast cancer cells MDA-MB-231 and 4T1 were treated with Nigericin sodium (0.25-20 μg/ml) for 24 h the cell viability o the cells was detected b the MTS. Results: Nigericin sodium dose-dependently inhibite the cell viability of MDA-MB-231 and 4T1 cells with IC50 of 2.881 μM and 2.505 μM, respectively METHODS: Human lung cancer cells H460 were treated with Nigericin sodium (1 μM) for 24-48 h. Cell migration and invasion were detected by Transwell. Results: Nigericin sodium significantly inhibite the migration and invasion of H460 cells.

Storage & Handling

• Storage: keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Disclaimer: For research use only

Alternative Names

Antibiotic, Bacterial, Nigericin, Nigericin sodium, Nigericin sodium salt, NLR, NLRP3, NODlikeReceptor(NLR), NOD-like Receptor (NLR), NOD-like Receptor, NODlike Receptor (NLR), NODlikeReceptor, KcsA, Inhibitor, inhibit, Potassium Channel, PotassiumChannel

Compound Identifiers

PubChem CID

16760591